Merck Says Fosamax Femur Fracture Claims Are Preempted

Law360, New York (January 16, 2013, 2:52 PM EST) -- Merck & Co. Inc. urged a New Jersey federal court Tuesday to dismiss part of a multidistrict litigation accusing it of negligence and other claims over femur fractures and similar injuries allegedly caused by its osteoporosis drug Fosamax, arguing those claims are preempted.

The drug company argued in a motion for summary judgment that plaintiff Bernadette Glynn's claims should be dismissed because they are premised on an alleged failure to warn, citing the U.S. Supreme Court's 2009 ruling in Wyeth v. Levine holding that state law...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

GLYNN et al v. MERCK SHARP & DOHME CORP.


Case Number

3:11-cv-05304

Court

New Jersey

Nature of Suit

Personal Inj. Prod. Liability

Judge

Joel A. Pisano

Date Filed

September 15, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.